A Phase 2, Randomized, Open-Label Study of Sofosbuvir/GS-5885 Fixed Dose Combination +/- Ribavirin in Subjects With Chronic Genotype 1 HCV Infection

Trial Profile

A Phase 2, Randomized, Open-Label Study of Sofosbuvir/GS-5885 Fixed Dose Combination +/- Ribavirin in Subjects With Chronic Genotype 1 HCV Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2016

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms LONESTAR
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 03 Dec 2016 Results of post treatment resistance analysis (n=51) using data from this and four other trials (NCT01260350, NCT01701401, NCT01768286, NCT01851330) published in the Journal of Hepatology
    • 21 Jan 2014 Status changed from active, no longer recruiting to completed as reported by the ClinicalTrials.gov record.
    • 08 Nov 2013 Results published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top